Monthly Archives: June 2017

Improved and Expanded Spastic Paraplegia Panel Now Available

MNG Laboratories understands the importance of providing your patients with the most comprehensive testing possible, particularly with disorders such as spastic paraplegia that are both clinically and genetically heterogeneous.  When it comes to our Spastic Paraplegia Panel, we guarantee coverage of all pathogenic variants in the most relevant genes while providing single-exon resolution copy number analysis. We routinely review over 2,500 disease causing variants in genes associated with conditions that are linked to spastic paraplegia. That’s over 3x more than our closest competitor!  To improve diagnostic sensitivity, single exon resolution copy number analysis and mitochondrial sequencing with deletion analysis is included. We strive to give you the best answers possible when you trust us with your patients’ samples. MNG constantly endeavors to provide you with actionable results. Utilizing our proprietary Genome MaNaGer™ pipeline and Neurogenetic Answers™ reporting process, we aim to reduce the distraction of unrelated variants of uncertain significance.

Redefining Your Comprehensive Intellectual Disability Panel

MNG Laboratories understands the importance of having a robust Comprehensive Intellectual Disability Panel to provide the answers your patients need. Our complete offering guarantees coverage of all pathogenic variants in the most relevant genes while providing single-exon resolution copy number analysis. We routinely review over 15,600 disease causing variants in genes associated with conditions that are linked to intellectual disability. That’s over 18% more than our closest competitor. Knowing how important time is to you and your patients, we deliver results in 2-4 weeks and offer a STAT option for results guaranteed within 2 weeks. We strive to give you the best answers possible when you trust us with your patients’ samples. MNG constantly endeavors to provide you with actionable results. Utilizing our proprietary Genome MaNaGer™ pipeline and Neurogenetic Answers™ reporting process, we aim to reduce the distraction of unrelated variants of uncertain significance.